StockNews.com assumed coverage on shares of Alimera Sciences (NASDAQ:ALIM – Get Rating) in a research note published on Thursday morning. The brokerage issued a hold rating on the biopharmaceutical company’s stock. A number of other equities analysts have also issued reports on the company. HC Wainwright lowered their price target on Alimera Sciences from $9.00 […]
StockNews.com started coverage on shares of Alimera Sciences (NASDAQ:ALIM – Get Rating) in a research note issued to investors on Thursday morning. The brokerage issued a hold rating on the biopharmaceutical company’s stock. A number of other research firms have also weighed in on ALIM. Craig Hallum reduced their target price on shares of Alimera […]
Investment analysts at StockNews.com began coverage on shares of Alimera Sciences (NASDAQ:ALIM – Get Rating) in a research report issued on Wednesday. The firm set a “hold” rating on the biopharmaceutical company’s stock. Several other analysts also recently issued reports on ALIM. Craig Hallum decreased their price objective on shares of Alimera Sciences from $18.00 […]
Alimera Sciences (NASDAQ:ALIM – Get Rating) had its target price trimmed by HC Wainwright from $9.00 to $5.00 in a research report released on Friday, The Fly reports. HC Wainwright also issued estimates for Alimera Sciences’ Q2 2023 earnings at ($0.22) EPS, Q3 2023 earnings at ($0.19) EPS, Q4 2023 earnings at ($0.10) EPS, FY2023 […]
Alimera Sciences, Inc. (NASDAQ:ALIM – Get Rating) – Stock analysts at HC Wainwright increased their Q2 2023 earnings estimates for Alimera Sciences in a research note issued to investors on Tuesday, May 16th. HC Wainwright analyst Y. Chen now forecasts that the biopharmaceutical company will post earnings of ($0.22) per share for the quarter, up […]